| Symbol | ERAS |
|---|---|
| Name | ERASCA, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 10835 ROAD TO THE CURE,SUITE 140, SAN DIEGO, California, 92121, United States |
| Telephone | +1 858 465-6511 |
| Fax | — |
| — | |
| Website | https://www.erasca.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001761918 |
| Description | Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The companys pipeline includes two clinical-stage programs (ERK and SHP2 inhibitors), two preclinical-stage programs (CNS-penetrant KRAS G12C and EGFR inhibitors), and seven discovery-stage programs targeting other key oncogenic drivers. Additional info from NASDAQ: |
Erasca 72 Hour Deadline Alert: Kahn Swick & Foti, LLC Reminds Investors With Losses In Excess Of $100,000 of Deadline in Class Action Lawsuit Against Erasca, Inc. - ERAS
Read moreINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Erasca, Inc. of Class Action Lawsuit and Upcoming Deadlines - ERAS
Read moreErasca, Inc. Deadline: ERAS Investors with Losses in Excess of $100K Have Opportunity to Lead Erasca, Inc. Securities Fraud Lawsuit
Read moreERAS INVESTOR ALERT: Erasca, Inc. Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit
Read moreERAS Investors Have Opportunity to Lead Erasca, Inc. Securities Fraud Lawsuit with SBS Law
Read moreErasca, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - ERAS
Read moreERAS INVESTOR ALERT: Erasca, Inc. Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit
Read moreThe Gross Law Firm Reminds Erasca, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of August 10, 2026 - ERAS
Read moreErasca, Inc. Deadline: ERAS Investors Have Opportunity to Lead Erasca, Inc. Securities Fraud Lawsuit
Read moreErasca, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - ERAS
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07021898 | A Study of ERAS-4001 in Patients With Advanced or Metastatic Solid Tumors. | Phase1 | Metastatic Solid Tumors | Recruiting | 2025-08-06 | 2028-12-01 | ClinicalTrials.gov |
| NCT06983743 | A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors | Phase1 | Metastatic Solid Tumors | Recruiting | 2025-06-05 | 2028-12-01 | ClinicalTrials.gov |
| NCT06346067 | A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patien… | Phase3 | Advanced or Metastatic NRAS-mutant Melanoma | Active_Not_Recruiting | 2024-04-29 | 2028-12-01 | ClinicalTrials.gov |
| NCT05907304 | A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patien… | Phase1 | Advanced or Metastatic Solid Tumors | Active_Not_Recruiting | 2023-08-17 | 2026-12-01 | ClinicalTrials.gov |
| NCT05279859 | A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With He… | Phase1 | Acute Myeloid Leukemia | Withdrawn | 2022-03-15 | 2025-06-01 | ClinicalTrials.gov |
| NCT05222802 | A Study to Evaluate ERAS-801 in Patients With Recurrent Glioblastoma (THUNDERBB… | Phase1 | Glioblastoma Multiforme | Active_Not_Recruiting | 2022-02-25 | 2025-09-30 | ClinicalTrials.gov |
| NCT05039177 | A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies | Phase1 | Metastatic Colorectal Cancer | Completed | 2021-09-20 | 2026-01-26 | ClinicalTrials.gov |
| NCT04959981 | A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Ad… | Phase1 | Advanced Non-squamous Non-small-cell Lung Cancer | Completed | 2021-09-02 | 2023-04-27 | ClinicalTrials.gov |
| NCT04866134 | A Study of ERAS-007 as Monotherapy or in Combination With ERAS-601 in Patients … | Phase1 | Advanced or Metastatic Solid Tumors | Active_Not_Recruiting | 2021-05-07 | 2027-01-01 | ClinicalTrials.gov |
| NCT04670679 | A Dose Escalation/Expansion Study of ERAS-601 in Patients With Advanced or Meta… | Phase1 | Advanced or Metastatic Solid Tumors | Active_Not_Recruiting | 2020-12-15 | 2026-06-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| ERAS-0015 in combination | Other | Phase PHASE1 | Metastatic Solid Tumors | RECRUITING | NCT06983743 |
| ERAS-0015 | Other | Phase PHASE1 | Metastatic Solid Tumors | RECRUITING | NCT06983743 |
| ERAS-0015 in combination | Other | Phase PHASE1 | Metastatic Solid Tumors | RECRUITING | NCT06983743 |
| ERAS-0015 | Other | Phase PHASE1 | Metastatic Solid Tumors | RECRUITING | NCT06983743 |
| ERAS-601 | Other | Phase PHASE1 | Advanced or Metastatic Solid Tumors | ACTIVE_NOT_RECRUITING | NCT04866134 |
| ERAS-007 | Other | Phase PHASE1 | Advanced or Metastatic Solid Tumors | ACTIVE_NOT_RECRUITING | NCT04866134 |
| ERAS-0015 in combination | Other | Phase PHASE1 | Metastatic Solid Tumors | RECRUITING | NCT06983743 |
| ERAS-0015 | Other | Phase PHASE1 | Metastatic Solid Tumors | RECRUITING | NCT06983743 |
| Gilteritinib | Other | Phase PHASE1 | Acute Myeloid Leukemia | WITHDRAWN | NCT05279859 |
| ERAS-601 | Other | Phase PHASE1 | Acute Myeloid Leukemia | WITHDRAWN | NCT05279859 |
| ERAS-007 | Other | Phase PHASE1 | Acute Myeloid Leukemia | WITHDRAWN | NCT05279859 |
| Sotorasib | Other | Phase PHASE1 | Advanced Non-squamous Non-small-cell Lung Cancer | COMPLETED | NCT04959981 |
| Osimertinib | Other | Phase PHASE1 | Advanced Non-squamous Non-small-cell Lung Cancer | COMPLETED | NCT04959981 |
| ERAS-601 | Other | Phase PHASE1 | Advanced Non-squamous Non-small-cell Lung Cancer | COMPLETED | NCT04959981 |
| ERAS-007 | Other | Phase PHASE1 | Advanced Non-squamous Non-small-cell Lung Cancer | COMPLETED | NCT04959981 |
| ERAS-601 | Other | Phase PHASE1 | Advanced or Metastatic Solid Tumors | ACTIVE_NOT_RECRUITING | NCT04866134 |
| ERAS-007 | Other | Phase PHASE1 | Advanced or Metastatic Solid Tumors | ACTIVE_NOT_RECRUITING | NCT04866134 |
| ERAS-801 | Other | Phase PHASE1 | Glioblastoma Multiforme | ACTIVE_NOT_RECRUITING | NCT05222802 |
| ERAS-0015 in combination | Other | Phase PHASE1 | Metastatic Solid Tumors | RECRUITING | NCT06983743 |
| ERAS-0015 | Other | Phase PHASE1 | Metastatic Solid Tumors | RECRUITING | NCT06983743 |
| ERAS-4001 in combination | Other | Phase PHASE1 | Metastatic Solid Tumors | RECRUITING | NCT07021898 |
| ERAS-4001 | Other | Phase PHASE1 | Metastatic Solid Tumors | RECRUITING | NCT07021898 |
| Trametinib | Other | Phase PHASE3 | Advanced or Metastatic NRAS-mutant Melanoma | ACTIVE_NOT_RECRUITING | NCT06346067 |
| Temozolomide | Other | Phase PHASE3 | Advanced or Metastatic NRAS-mutant Melanoma | ACTIVE_NOT_RECRUITING | NCT06346067 |
| Dacarbazine | Other | Phase PHASE3 | Advanced or Metastatic NRAS-mutant Melanoma | ACTIVE_NOT_RECRUITING | NCT06346067 |
| Naporafenib | Other | Phase PHASE3 | Advanced or Metastatic NRAS-mutant Melanoma | ACTIVE_NOT_RECRUITING | NCT06346067 |
| Trametinib | Other | Phase PHASE1 | Advanced or Metastatic Solid Tumors | ACTIVE_NOT_RECRUITING | NCT05907304 |
| Naporafenib | Other | Phase PHASE1 | Advanced or Metastatic Solid Tumors | ACTIVE_NOT_RECRUITING | NCT05907304 |
| Palbociclib | Other | Phase PHASE1 | Metastatic Colorectal Cancer | COMPLETED | NCT05039177 |
| Cetuximab | Other | Phase PHASE1 | Metastatic Colorectal Cancer | COMPLETED | NCT05039177 |
| Encorafenib | Other | Phase PHASE1 | Metastatic Colorectal Cancer | COMPLETED | NCT05039177 |
| ERAS-007 | Other | Phase PHASE1 | Metastatic Colorectal Cancer | COMPLETED | NCT05039177 |
| Pembrolizumab | Other | Phase PHASE1 | Advanced or Metastatic Solid Tumors | ACTIVE_NOT_RECRUITING | NCT04670679 |
| Cetuximab | Other | Phase PHASE1 | Advanced or Metastatic Solid Tumors | ACTIVE_NOT_RECRUITING | NCT04670679 |
| ERAS-601 | Other | Phase PHASE1 | Advanced or Metastatic Solid Tumors | ACTIVE_NOT_RECRUITING | NCT04670679 |
| ERAS-4001 in combination | DRUG | Phase PHASE1 | Metastatic Solid Tumors | RECRUITING | NCT07021898 |
| ERAS-4001 | DRUG | Phase PHASE1 | Metastatic Solid Tumors | RECRUITING | NCT07021898 |
| ERAS-0015 in combination | DRUG | Phase PHASE1 | Metastatic Solid Tumors | RECRUITING | NCT06983743 |
| ERAS-0015 | DRUG | Phase PHASE1 | Metastatic Solid Tumors | RECRUITING | NCT06983743 |
| Temozolomide | DRUG | Phase PHASE3 | Advanced or Metastatic NRAS-mutant Melanoma | ACTIVE_NOT_RECRUITING | NCT06346067 |
| Dacarbazine | DRUG | Phase PHASE3 | Advanced or Metastatic NRAS-mutant Melanoma | ACTIVE_NOT_RECRUITING | NCT06346067 |
| Trametinib | DRUG | Phase PHASE3 | Advanced or Metastatic NRAS-mutant Melanoma | ACTIVE_NOT_RECRUITING | NCT06346067 |
| Naporafenib | DRUG | Phase PHASE3 | Advanced or Metastatic NRAS-mutant Melanoma | ACTIVE_NOT_RECRUITING | NCT06346067 |
| Gilteritinib | DRUG | Phase PHASE1 | Acute Myeloid Leukemia | WITHDRAWN | NCT05279859 |
| ERAS-801 | DRUG | Phase PHASE1 | Glioblastoma Multiforme | ACTIVE_NOT_RECRUITING | NCT05222802 |
| Palbociclib | DRUG | Phase PHASE1 | Metastatic Colorectal Cancer | COMPLETED | NCT05039177 |
| Encorafenib | DRUG | Phase PHASE1 | Metastatic Colorectal Cancer | COMPLETED | NCT05039177 |
| Sotorasib | DRUG | Phase PHASE1 | Advanced Non-squamous Non-small-cell Lung Cancer | COMPLETED | NCT04959981 |
| Osimertinib | DRUG | Phase PHASE1 | Advanced Non-squamous Non-small-cell Lung Cancer | COMPLETED | NCT04959981 |
| ERAS-007 | DRUG | Phase PHASE1 | Acute Myeloid Leukemia | WITHDRAWN | NCT05279859 |
| Pembrolizumab | DRUG | Phase PHASE1 | Advanced or Metastatic Solid Tumors | ACTIVE_NOT_RECRUITING | NCT04670679 |
| Cetuximab | DRUG | Phase PHASE1 | Metastatic Colorectal Cancer | COMPLETED | NCT05039177 |
| ERAS-601 | DRUG | Phase PHASE1 | Acute Myeloid Leukemia | WITHDRAWN | NCT05279859 |